Isabelle Riviere, PhD

Screen-Shot-2017-09-11-at-12-33-45-PM.pngMy laboratory investigates genetic approaches to enhance various cell types including T lymphocytes and hematopoietic stem cells for the treatment of cancer and genetic blood disorders.

Over the past 18 years, I have developed cell manufacturing processes for several Phase I/II clinical trials under current Good Manufacturing Practices in the academic setting in order i- to genetically modify and expand T lymphocytes and dendritic cells ii- to genetically modify CD34+ HPSCs iii- to manufacture clinical retroviral vectors and ancillary cells.

My lab currently supports multiple CAR-T cell based clinical trials for the treatment of hematological malignancies and solid tumors. I also investigate immunological functions of CAR T cells in clinical trials and in animal models. I serve as contact with CBER and FDA for the manufacture and biosafety testing of all biological materials including patient cells and viral vectors at MSK. I have been involved in co-organizing the Clinical Trials training courses at the American Society of Gene and Cell Therapy (ASGCT) (2014, 2017) and at the International Society for Stem Cell Research (ISSCR) (2016) annual meetings.

I actively participate in the National Cell Manufacturing Consortium Workshops that have led to the establishment of the “Technology Roadmap to 2025 for Achieving Large Scale, Cost effective, Reproducible Manufacturing of High-Quality Cells”. My laboratory is part of the newly funded National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) network.


Board & Officers

The ASGCT Board of Directors and the Society's officers have full responsibility for the management, direction and control of the Society.


ASGCT Policy Summit

September 23-25, 2020